-
1.发明申请
公开(公告)号：WO2007079558B1
公开(公告)日：2007-10-04
申请号：PCT/BR2007000003
申请日：2007-01-05
Applicant: PEP FARMA CONSULTORIA E DESENV , CAMARGO ANTONIO , IANZER DANIELLE , SILVA CARLOS , GOMES CLAUDIANA , GUERREIRO JULIANO
Inventor： CAMARGO ANTONIO , IANZER DANIELLE , SILVA CARLOS , GOMES CLAUDIANA , GUERREIRO JULIANO
Abstract: The present invention provides oligopeptides with amino acid sequences comprised in set forth in SEQ ID NO 1 to 18, capable of binding to diverse targets, generating increase and sustenance to nitric oxide (NO) production in mammalian cells, potentiate the argininosuccinate synthase activity of animal cells and/or increase the intracellular bivalent calcium ion in animal cells. Also disclosed are pharmaceutical compositions of one or more peptides described in the present invention. The invention further relates to the use of these peptides.
-
2.发明申请ANALGESIC PEPTIDES DERIVED FROM THE VENOM OF CROTALUS DURISSUS TERRIFICUSS SNAKES 审中-公开来自US US US S THE THE ES ES ES ES ES ES ES ES ES ES ES ES ES ES
公开(公告)号：WO2005107357A3
公开(公告)日：2007-05-24
申请号：PCT/BR2005000073
申请日：2005-05-06
Applicant: LABORATORIOS BIOSINTETICA LTDA , FUNDACAO DE AMPARO A PESQUISA , CURY YARA , PICOLO GISELE , KONNO KATSUHIRO , GIORGI RENATA , BRIGATTE PATRICIA , GUTIERREZ VANESSA , CAMARGO ANTONIO
Inventor： CURY YARA , PICOLO GISELE , KONNO KATSUHIRO , GIORGI RENATA , BRIGATTE PATRICIA , GUTIERREZ VANESSA , CAMARGO ANTONIO
CPC classification number: C07K14/46 , A61K38/00 , C07K7/08 , G01N2800/2842
Abstract: The present invention refers to analog compounds of peptides having the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, including analgesic peptides derived from snakes of species such as Crotalus durissus terrificus ; their uses in the treatment, diagnosis and prevention of painful conditions or mediated by opioid receptors, their pharmaceutical compositions and their methods of preparation and purification, including their uses in the identification of analgesic compounds.
Abstract translation: 本发明涉及具有氨基酸序列SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：3或SEQ ID NO：4的肽的类似物，包括衍生自诸如Crotalus durissus之类的蛇类的止痛肽 可怕的 其用于治疗，诊断和预防疼痛状况或由阿片受体介导的药物组合物及其制备和纯化方法，包括其用于鉴定止痛化合物的用途。
-
3.发明申请PHARMACEUTICAL COMPOSITIONS OF PEPTIDES, SECRETED BY THE VENOM GLANDS OF SNAKES, ESPECIALLY BOTHROPS JARARACA, EVASINS, ANALOGUES, DERIVATIVES AND ASSOCIATED PRODUCTS FOR EMPLOYMENT AS MODULATORS OF ACETYLCHOLINE RECEPTOR FUNCTION. 审中-公开由蛇毒VENOM GLANDS分泌的肽的药物组合物，特别是JARARACA，EVASINS，类似物，衍生物和用于作为乙酰胆碱受体功能调节剂的相关产品的组合物。
公开(公告)号：WO2005081613A2
公开(公告)日：2005-09-09
申请号：PCT/BR2005/000015
申请日：2005-02-04
Applicant: BIOLAB SANUS FARMACÊUTICA LTDA. , FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP , HAYASHI, Mirian Akemi Furuie , CAMARGO, Antonio Carlos Martins de , ULRICH, Alexander Henning , MILLÁN, Rubén Dario Sinisterra , SANTOS, Robson Augusto Souza dos , IANZER, Danielle Alves , MARIONI, Raphael dos Reis , SILVA, Carlos Alberto da
Inventor： HAYASHI, Mirian Akemi Furuie , CAMARGO, Antonio Carlos Martins de , ULRICH, Alexander Henning , MILLÁN, Rubén Dario Sinisterra , SANTOS, Robson Augusto Souza dos , IANZER, Danielle Alves , MARIONI, Raphael dos Reis , SILVA, Carlos Alberto da
Abstract: The present invention refers to the employment of pharmaceutical compositions of snake venom glands secreted peptides, particularly from Bothrops jararaca, EVASINS, and analogous and derivatives compounds, and associated products, as modulating agents of the acetylcholine receptors. The pharmaceutical compositions of the present invention are characterized by acting as agonist, partial agonist, antagonist or alosteric modulators of the acetylcholine receptors. The pharmaceutical compostions of EVASINS also refer to the use of these compounds to protect the acetycholine receptors against the action of toxins, such as the phylantotoxins or cembranoids isolated from the coral or tobacco, or also spider toxins. The pharmaceutical compositions of EVASINS are characterized by the ability to prevent the binding of the cocaine to the acetylcholine receptors. The pharmaceutical compostions of EVASINS and their structural and/or conformational analogues characterized by the employment of EVASINS and their respective analogues and derivatives refer to the use as molecular models for the development of drugs and/or pharmaceutical compositions based on peptidic and/or non-peptidic compounds for the use in the diagnosis, prevention, study and treatment of diseases associated with the cholinergic receptors disfunctions. The pharmaceutical compositions of the mentioned EVASINS, analogues and derivatives included into cyclodextrins and derivatives, of the present patent show an increase of the biodisponibility, duration and/or efficacy of the modulating effects on the acetylcholine receptors once inoculated by different administration routes such as oral, intravenous, intramuscle, nasal, subcutaneous, transdermic, as non-limiting examples.
Abstract translation: 本发明涉及使用蛇毒腺分泌肽的药物组合物，特别是来自Bothrops jararaca，EVASINS以及类似和衍生物化合物以及相关产物作为乙酰胆碱受体的调节剂。 本发明的药物组合物的特征在于充当乙酰胆碱受体的激动剂，部分激动剂，拮抗剂或变构调节剂。 EVASINS的药物组合物还涉及使用这些化合物保护乙酰胆碱受体免于毒素的作用，例如从珊瑚或烟草中分离的乙基毒素或西松烷类，或者还有蜘蛛毒素。 EVASINS的药物组合物的特征在于能够防止可卡因与乙酰胆碱受体结合。 以使用EVASINS及其各自的类似物和衍生物为特征的EVASINS及其结构和/或构象类似物的药物组合物指作为分子模型用于开发基于肽和/或非肽的药物和/或药物组合物的分子模型， 用于诊断，预防，研究和治疗与胆碱能受体功能障碍相关的疾病。 本专利提及的包含在环糊精和衍生物中的所提及的EVASINS，其类似物和衍生物的药物组合物显示一旦通过不同的给药途径例如口服接种，对乙酰胆碱受体的调节作用的生物指数，持续时间和/或功效增加 ，静脉内，肌内，鼻内，皮下，透皮，作为非限制性实例。
-
4.发明申请ISOLATION AND PURIFICATION PROCEDURE OF VASOPEPTIDASE PEPTIDE INHIBITORS 审中-公开VASEPEPTIDASE PEPTIDE抑制剂的分离和纯化程序
公开(公告)号：WO02074782A2
公开(公告)日：2002-09-26
申请号：PCT/BR0200041
申请日：2002-03-18
Applicant: BIOLAB SANUS FARMACEUTICA LTDA , FUNDACAO DE AMPARO A PESQUISA , MARTINS DE CAMARGO ANTONIO CAR , CALHETA VIEIRA PORTARO FERNAND , FERRAGINI MURBACK ALESSANDRA , ALVES IANZER DANIELLE , POLISELLI FARSKY SANDRA HELENA , PALMA MARIO SERGIO
Inventor： MARTINS DE CAMARGO ANTONIO CAR , CALHETA VIEIRA PORTARO FERNAND , FERRAGINI MURBACK ALESSANDRA , ALVES IANZER DANIELLE , POLISELLI FARSKY SANDRA HELENA , PALMA MARIO SERGIO
IPC: G01N27/62 , A61K38/00 , A61P9/08 , A61P9/12 , A61P43/00 , B01J20/281 , C07K1/10 , C07K7/06 , C07K7/08 , C12N9/64 , C12N9/99 , C12N15/09 , C12Q1/68 , G01N27/447 , G01N30/34 , G01N30/46 , G01N30/72 , G01N30/88 , G01N33/53 , G01N33/566 , G01N33/60 , C07K
CPC classification number: C12N9/6418 , A61K38/00
Abstract: The present invention patent refers to the isolation and purification of peptides secreted by serpent venom glands, specifically Bothrops jararaca; to the peptide thus obtained, as well as to the production procedures by genetic engineering techniques in procaryotic and eukaryotic systems; to the engineered peptide thus obtained; to the production of said peptide by chemical synthesis, as well as to the peptide resulting from this chemical processing. It also refers to the utilization of said peptides, obtained by different procedures, in distinct pharmaceutical compositions, and introduced into the organism by a variety of means, in order for them to act as inhibitors of vasopeptidases, and consequently reduce systemic arterial blood pressure, and show local vasodilating action.
Abstract translation: 本发明专利是指分离和纯化由蛇毒腺分泌的肽，特别是Bothrops jararaca; 涉及由此获得的肽，以及通过基因工程技术在原核和真核系统中的生产程序; 与由此获得的工程化肽反应; 通过化学合成生产所述肽，以及由该化学处理产生的肽。 它还指通过不同方法获得的所述肽在不同的药物组合物中的利用，并通过多种方法引入生物体，以使它们作为血管肽酶的抑制剂，从而降低全身动脉血压， 并显示局部血管扩张作用。
-
Patent Agency Ranking5.发明申请
公开(公告)号：WO2007079558A3
公开(公告)日：2007-07-19
申请号：PCT/BR2007/000003
申请日：2007-01-05
Applicant: PEP FARMA CONSULTORIA E DESENVOLVIMENTO FARMACÊUTICO LTDA , CAMARGO, Antonio , IANZER, Danielle , SILVA, Carlos , GOMES, Claudiana , GUERREIRO, Juliano
Inventor： CAMARGO, Antonio , IANZER, Danielle , SILVA, Carlos , GOMES, Claudiana , GUERREIRO, Juliano
Abstract: The present invention provides oligopeptides with amino acid sequences comprised in set forth in SEQ ID NO 1 to 18, capable of binding to diverse targets, generating increase and sustenance to nitric oxide (NO) production in mammalian cells, potentiate the argininosuccinate synthase activity of animal cells and/or increase the intracellular bivalent calcium ion in animal cells. Also disclosed are pharmaceutical compositions of one or more peptides described in the present invention. The invention further relates to the use of these peptides.
-
6.发明申请PROLINE-RICH PEPTIDES, PHARMACEUTICAL COMPOSITION, USE OF ONE OR MORE PEPTIDES AND METHOD OF TREATMENT 审中-公开富含脯氨酸的肽，药物组合物，一种或多种肽的使用和治疗方法
公开(公告)号：WO2007079558A2
公开(公告)日：2007-07-19
申请号：PCT/BR2007000003
申请日：2007-01-05
Applicant: PEP FARMA CONSULTORIA E DESENV , CAMARGO ANTONIO , IANZER DANIELLE , SILVA CARLOS , GOMES CLAUDIANA , GUERREIRO JULIANO
Inventor： CAMARGO ANTONIO , IANZER DANIELLE , SILVA CARLOS , GOMES CLAUDIANA , GUERREIRO JULIANO
Abstract: The present invention provides oligopeptides with amino acid sequences comprised in set forth in SEQ ID NO 1 to 18, capable of binding to diverse targets, generating increase and sustenance to nitric oxide (NO) production in mammalian cells, potentiate the argininosuccinate synthase activity of animal cells and/or increase the intracellular bivalent calcium ion in animal cells. Also disclosed are pharmaceutical compositions of one or more peptides described in the present invention. The invention further relates to the use of these peptides.
Abstract translation: 本发明提供了具有包含在SEQ ID NO 1至18中的氨基酸序列的寡肽，其能够结合不同的靶，产生对哺乳动物细胞中一氧化氮（NO）产生的增加和维持，增强动物的精氨琥珀酸合酶活性 细胞和/或增加动物细胞中的细胞内二价钙离子。 还公开了本发明中描述的一种或多种肽的药物组合物。 本发明进一步涉及这些肽的用途。
-
公开(公告)号：WO2004053052A3
公开(公告)日：2006-08-03
申请号：PCT/BR0300189
申请日：2003-12-08
Applicant: CAMARGO ANTONIO , HAYASHI MIRIAN , PORTARO FERNANDA , GUERREIRO JULIANO
Inventor： CAMARGO ANTONIO , HAYASHI MIRIAN , PORTARO FERNANDA , GUERREIRO JULIANO
IPC: C12N9/64
CPC classification number: C12N9/6421
Abstract: This invention refers to a process for the determination of the primary structure of the mRNA coding for human endooligopeptidase A (hEOPA) and its protein sequence. In addition, the invention relates to a process for the determination of the structure of the hEOPA gene and the production of recombinant hEOPA. Furthermore, the invention relates to a process of generating antibodies against hEOPA in mice.
Abstract translation: 本发明涉及确定编码人内寡肽酶A（hEOPA）的mRNA及其蛋白质序列的一级结构的方法。 此外，本发明涉及确定hEOPA基因的结构和重组hEOPA的产生的方法。 此外，本发明涉及在小鼠中产生针对hEOPA的抗体的方法。
-
8.发明申请PHARMACEUTICAL COMPOSITIONS OF PEPTIDES SECRETED BY THE VENOM GLANDS OF SNAKES 审中-公开通过血管内皮细胞分泌的肽的药物组合物
公开(公告)号：WO2005081613A3
公开(公告)日：2005-10-13
申请号：PCT/BR2005000015
申请日：2005-02-04
Applicant: BIOLAB SANUS FARMACEUTICA LTDA , FUNDACAO DE AMPARO A PESQUISA , HAYASHI MIRIAN AKEMI FURUIE , CAMARGO ANTONIO CARLOS MARTINS , ULRICH ALEXANDER HENNING , MILLAN RUBEN DARIO SINISTERRA , SANTOS ROBSON AUGUSTO SOUZA DO , IANZER DANIELLE ALVES , MARIONI RAPHAEL DOS REIS , SILVA CARLOS ALBERTO DA
Inventor： HAYASHI MIRIAN AKEMI FURUIE , CAMARGO ANTONIO CARLOS MARTINS , ULRICH ALEXANDER HENNING , MILLAN RUBEN DARIO SINISTERRA , SANTOS ROBSON AUGUSTO SOUZA DO , IANZER DANIELLE ALVES , MARIONI RAPHAEL DOS REIS , SILVA CARLOS ALBERTO DA
Abstract: The present invention refers to the employment of pharmaceutical compositions of snake venom glands secreted peptides, particularly from Bothrops jararaca, EVASINS, and analogous and derivatives compounds, and associated products, as modulating agents of the acetylcholine receptors. The pharmaceutical compositions of EVASINS are characterized by the ability to prevent the binding of the cocaine to the acetylcholine receptors.
Abstract translation: 本发明涉及使用蛇毒腺体分泌肽的药物组合物，特别是来自Bothrops jararaca，EVASINS，以及类似和衍生物化合物及其相关产品作为乙酰胆碱受体的调节剂。 EVASINS的药物组合物的特征在于防止可卡因与乙酰胆碱受体结合的能力。
-
9.发明申请PHARMACEUTICAL COMPOSITIONS PREPARATION OF PEPTIDES, SECRETED BY THE SNAKE VENOM GLANDS 审中-公开药物组合物由SNAKE VENOM GLANDS分泌的肽的制备
公开(公告)号：WO2004052273A3
公开(公告)日：2005-04-21
申请号：PCT/BR0300192
申请日：2003-12-09
Applicant: BIOLAB SANUS FARMACEUTICA LTDA , CAMARGO ANTONIO , SANTOS ROBSON , MILLAN RUBEN , IANZER DANIELLE
Inventor： CAMARGO ANTONIO , SANTOS ROBSON , MILLAN RUBEN , IANZER DANIELLE
CPC classification number: A61K9/19 , A61K35/58 , A61K38/17 , A61K38/57 , A61K47/40 , A61K47/6951 , B82Y5/00 , C07K14/46 , C07K14/463 , C07K14/811
Abstract: The present invention is characterized by the process of preparation of pharmaceutical compositions for the development of applications of the Evasins and their structural and/or conformational analogues in chronic-degenerative diseases. It s further characterized by the process of preparation of pharmaceutical compositions and related products of the Evasins peptides and their structural and/or conformational analogues in using the cyclodextrins, its derivatives, liposomes and biodegradable polymers and/or mixture of these systems.The present invention is also characterized by the identification of new biochemical and physio-pharmacological mechanisms not related to the effects on the bradykinin metabolism and angiotensin II formation, which contributes for the mechanism of action of these peptides in chronic-degenerative disorders. In the state-of-art no application was found which uses the Evasins and their analogues included in the cyclodextrins, liposomes, the biodegradable polimers and their derivatives, for the study and treatment of hypertension or other cardiovascular or chronic-degenerative diseases. This characterizes the present invention as a new and more efficient alternative for the study and treatment of these pathologies and their complications.It is further characterized by the increased efficacy of these peptides and their analogues included in cyclodextrins, when administered to rats. This characterizes an increased biodisponibility of these peptides and their analogues using the compositions of the present invention.
Abstract translation: 本发明的特征在于制备用于开发Evasin及其结构和/或构象类似物在慢性退行性疾病中的应用的药物组合物的方法。 其进一步的特征在于制备使用环糊精，其衍生物，脂质体和可生物降解的聚合物和/或这些系统的混合物的Evasins肽及其结构和/或构象类似物的药物组合物和相关产物的方法。本发明 其特征还在于鉴定与缓激肽代谢和血管紧张素II形成的作用无关的新的生化和物理 - 药理学机制，这有助于这些肽在慢性退行性疾病中的作用机制。 在最先进的技术中，没有发现使用包含在环糊精，脂质体，可生物降解的聚合物及其衍生物中的Evasin及其类似物用于研究和治疗高血压或其它心血管或慢性退行性疾病的应用。 这将本发明描述为用于研究和治疗这些病症及其并发症的新的和更有效的替代方案。进一步的特征在于当给予大鼠时，这些肽及其包括在环糊精中的类似物的功效增加。 这表明使用本发明的组合物增加这些肽及其类似物的生物可分性。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.01 seconds)
